Accepted Manuscript Sixteen Years Later and the Debate for TAVR or SAVR Remains Controversial Saina Attaran, MD, Vinod H. Thourani, MD PII: S0022-5223(18)30624-X DOI: 10.1016/j.jtcvs.2018.02.080 Reference: YMTC 12675 To appear in: The Journal of Thoracic and Cardiovascular Surgery Received Date: 25 February 2018 Accepted Date: 28 February 2018 Please cite this article as: Attaran S, Thourani VH, Sixteen Years Later and the Debate for TAVR or SAVR Remains Controversial, The Journal of Thoracic and Cardiovascular Surgery (2018), doi: 10.1016/j.jtcvs.2018.02.080. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Attaran and Thourani. Comparison of TAVR and SAVR 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Sixteen Years Later and the Debate for TAVR or SAVR Remains Controversial Saina Attaran, MD and Vinod H. Thourani, MD, Department of Cardiac Surgery, MedStar Heart and Vascular Institute, Georgetown University, Washington, DC Correspondence: Vinod H. Thourani, MD Department of Cardiac Surgery Medstar Heart and Vascular Institute 110 Irving St, Room 6D15G Washington, DC 20010 Email: vinod.h.thourani@medstar.net Phone: 202-877-7464 Fax: 202-877-3504
Attaran and Thourani. Comparison of TAVR and SAVR 2 25 26 27 28 29 30 Central Picture Legend: Saina Attaran, MD Central Message: The management of aortic stenosis requires a dedicated heart valve team of surgeons and cardiologists to determine the most appropriate procedure for that specific patient.
Attaran and Thourani. Comparison of TAVR and SAVR 3 31 Catheter-based approach of the treatment of aortic stenosis initiated with 32 balloon aortic valvuloplasty in the 1980s 1. Nearly 20 years later, the first 33 transcatheter aortic valve implantation in a human was performed in France by Alain 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 Cribier in 2002 2. For almost another sixteen years, numerous randomized and registry investigations have been conducted with the hopes of optimizing the appropriate treatment strategy for the management of severe aortic valve stenosis. In the current study by Armoiry et al 3, the authors have eloquently performed a propensity-matched comparison between high risk patients undergoing transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) in France during 2010. They have reported follow up data of up to five years based on a very strong French database or Medical Information System, decreasing the chances of patients missing to follow up. Another important endpoint included the economic evaluation and assessment between the two groups, a critical factor that is not available in most previously published series. They have reported a similar outcome between SAVR and TAVR in regards to mortality, re-operation, myocardial infarction, and stroke at one year. This is comparable to outcomes from the randomized controlled trials with the balloon- and self-expandable trials in the US. 4-5 However, from the one to five-year follow up, Armoiry et al note a trend towards increasing the risk of mortality, re-operation and stroke in the TAVR group compared with SAVR. 3 This is in contrast to the 5 year follow up in the high risk trial with the SAPIEN valve, in which there was similar rates of morbidity and mortality between SAVR and TAVR. 6 53 54 55 It is important to note some limitations of the current study, which is based on a national administrative database. Since the authors did not provide any of the commonly reported risk scores (the Society of Thoracic Surgeons or EuroSCORE II),
Attaran and Thourani. Comparison of TAVR and SAVR 4 56 57 it remain questionable which patient population the authors are actually representing. Clearly in 2010, if the patients were too high risk for surgery or had extreme frailty 58 they underwent TAVR and not SAVR. There are also several factors such as 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 porcelain aorta or dementia that can increase the possibility of a patient undergoing TAVR which may demonstrate a higher mortality and explain the differences seen at longer-term follow-up. It is difficult to adjust for those variables in this current propensity matched analysis. The amount of precise pre- and peri-procedural granularity is not available in the current administrative database study. For example, in 2010, the only commercial available TAVR device was a 1 st generation device, of which ~45% of patients generally underwent transapical TAVR. A breakdown of the transfemoral and transapical TAVR would have been extremely helpful. Especially since it has been well documented that transapical TAVR has a similar or even worse prognosis when compared to SAVR. It remains extremely important to report real-world data as new technology becomes available worldwide. However, results of administrative database registries without pre- or procedural granularity should be interpreted with caution. Long-term follow-up of randomized trials remains paramount and should drive guideline modification and clinical practice. Maybe the more controversial topic really lies in the comparison of TAVR or SAVR in low risk patients, since the 2 randomized low- risk trials have completed enrolment and are poised to be reported in 2019.
Attaran and Thourani. Comparison of TAVR and SAVR 5 78 79 80 REFERENCES 1. Lababidi Z. Aortic balloon valvuloplasty. Am Heart J. 1983;106:751-2. 2. Cribier A1, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106:3006-8. 3. Armoiry X, Obadia J-F, Pascal L, Polazzi S, and Duclos A. Comparison of transcatheter to surgical aortic valve implantation in high risk patients: a nationwide study in France. J Thorac Cardiovasc Surg. 2018: 4. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aorticvalve replacement in high-risk patients. N Eng J Med. 2011;364:2187-98. 5. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Eng J Med. 2014;370:1790-8. 6. Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2477-84. 7. Latib A, Maisano F, Bertoldi L, et al. Transcatheter vs surgical aortic valve replacement in intermediate-surgical-risk patients with aortic stenosis: a propensity score-matched case- control study. American heart journal. 2012;164:910-7.